A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, 4-Period Crossover Trial to Assess the Effect of Anagrelide Hydrochloride on QT/QTc Interval in Healthy Men and Women.

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, 4-Period Crossover Trial to Assess the Effect of Anagrelide Hydrochloride on QT/QTc Interval in Healthy Men and Women.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs Anagrelide (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Thrombocytosis
  • Focus Adverse reactions
  • Sponsors Shire
  • Most Recent Events

    • 30 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top